Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1967 1
1972 1
1973 1
1974 1
1975 1
1976 3
1980 1
1985 1
1986 1
1987 2
1990 2
1991 1
1992 4
1993 3
1994 1
1995 4
1996 10
1997 3
1998 5
1999 9
2000 14
2001 11
2002 29
2003 28
2004 24
2005 31
2006 30
2007 37
2008 43
2009 36
2010 36
2011 37
2012 65
2013 74
2014 89
2015 103
2016 81
2017 72
2018 80
2019 73
2020 86
2021 83
2022 94
2023 80
2024 39

Text availability

Article attribute

Article type

Publication date

Search Results

1,256 results

Results by year

Filters applied: . Clear all
Page 1
Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
Rocchetti M, Sala L, Rizzetto R, Staszewsky LI, Alemanni M, Zambelli V, Russo I, Barile L, Cornaghi L, Altomare C, Ronchi C, Mostacciuolo G, Lucchetti J, Gobbi M, Latini R, Zaza A. Rocchetti M, et al. Cardiovasc Res. 2014 Oct 1;104(1):37-48. doi: 10.1093/cvr/cvu188. Epub 2014 Aug 18. Cardiovasc Res. 2014. PMID: 25139747
AIMS: Pulmonary arterial hypertension (PAH) reflects abnormal pulmonary vascular resistance and causes right ventricular (RV) hypertrophy. Enhancement of the late sodium current (INaL) may result from hypertrophic remodelling. The study tests whether: (i) constitutive I …
AIMS: Pulmonary arterial hypertension (PAH) reflects abnormal pulmonary vascular resistance and causes right ventricular (RV) hypertrophy. E …
A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current.
Yang PC, Song Y, Giles WR, Horvath B, Chen-Izu Y, Belardinelli L, Rajamani S, Clancy CE. Yang PC, et al. J Physiol. 2015 Mar 15;593(6):1429-42. doi: 10.1113/jphysiol.2014.279554. J Physiol. 2015. PMID: 25545172 Free PMC article.
Recently, a novel compound that preferentially and potently reduces INaL, GS-458967 (IC50 for block of INaL = 130 nM) has been studied. ...GS-458967 (0.1 muM) caused a 28.67% block of INaL and 12.57% APD shortening in experiments, while the model predicted 10 …
Recently, a novel compound that preferentially and potently reduces INaL, GS-458967 (IC50 for block of INaL = 130 nM) has been …
Reply.
Yılmaz N, Seven B, Timur H, Yorgancı A, İnal HA, Kalem MN, Kalem Z, Han Ö, Bilezikçi B. Yılmaz N, et al. J Chin Med Assoc. 2018 Nov;81(11):1015. doi: 10.1016/j.jcma.2018.07.003. Epub 2018 Sep 7. J Chin Med Assoc. 2018. PMID: 30201190 Free article. No abstract available.
A single n-type semiconducting polymer-based photo-electrochemical transistor.
Druet V, Ohayon D, Petoukhoff CE, Zhong Y, Alshehri N, Koklu A, Nayak PD, Salvigni L, Almulla L, Surgailis J, Griggs S, McCulloch I, Laquai F, Inal S. Druet V, et al. Nat Commun. 2023 Sep 7;14(1):5481. doi: 10.1038/s41467-023-41313-7. Nat Commun. 2023. PMID: 37673950 Free PMC article.
Ranolazine in the prevention of anthracycline cardiotoxicity.
Corradi F, Paolini L, De Caterina R. Corradi F, et al. Pharmacol Res. 2014 Jan;79:88-102. doi: 10.1016/j.phrs.2013.11.001. Epub 2013 Nov 21. Pharmacol Res. 2014. PMID: 24269342 Review.
Ranolazine is a selective inhibitor of the cardiomyocyte late inward sodium current, INaL, and features anti-ischemic, antiarrhythmic and ATP-sparing actions. ...We hypothesize that anthracyclines may induce both INaL hyperactivation and an oxidative/energetic vicio …
Ranolazine is a selective inhibitor of the cardiomyocyte late inward sodium current, INaL, and features anti-ischemic, antiarrhythmic …
[The late sodium current: pathophysiology and pharmacology of a new therapeutic target].
Zaza A. Zaza A. G Ital Cardiol (Rome). 2011 Oct;12(10 Suppl 2):3S-11S. doi: 10.1714/946.10359. G Ital Cardiol (Rome). 2011. PMID: 21947134 Review. Italian.
However, a large body of evidence indicates that the "late" component of INa (INaL) may be enhanced in diseased myocardium. INaL enhancement has consequences on the electrical stability, contractile function and metabolism of cardiac myocytes, which may significantl …
However, a large body of evidence indicates that the "late" component of INa (INaL) may be enhanced in diseased myocardium. INaL …
Late sodium current (INaL) in pancreatic beta-cells.
Rizzetto R, Rocchetti M, Sala L, Ronchi C, Villa A, Ferrandi M, Molinari I, Bertuzzi F, Zaza A. Rizzetto R, et al. Pflugers Arch. 2015 Aug;467(8):1757-68. doi: 10.1007/s00424-014-1613-0. Epub 2014 Sep 20. Pflugers Arch. 2015. PMID: 25236919
INaL was identified as steady-state current blocked by 10 muM RAN (IRAN) or 0.5 muM tetrodotoxin (TTX) (ITTX). Veratridine (VERA, 40 muM) was used as INaL enhancer. Baseline INaL was similar between INS-1E and human islet cells. ...
INaL was identified as steady-state current blocked by 10 muM RAN (IRAN) or 0.5 muM tetrodotoxin (TTX) (ITTX). Veratridine (VERA, 40 …
1,256 results